162 related articles for article (PubMed ID: 1640002)
1. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers.
Tse FL; Jaffe JM; Troendle A
J Clin Pharmacol; 1992 Jul; 32(7):630-8. PubMed ID: 1640002
[TBL] [Abstract][Full Text] [Related]
2. Disposition of [3H]fluvastatin following single oral doses in beagle dogs and rhesus monkeys with bile fistulae.
Tse FL; Dain JG; Kalafsky G
Biopharm Drug Dispos; 1995 Apr; 16(3):211-9. PubMed ID: 7787133
[TBL] [Abstract][Full Text] [Related]
3. Disposition of fluvastatin, an inhibitor of HMG-COA reductase, in mouse, rat, dog, and monkey.
Tse FL; Smith HT; Ballard FH; Nicoletti J
Biopharm Drug Dispos; 1990; 11(6):519-31. PubMed ID: 2207302
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications of the biopharmaceutical properties of fluvastatin.
Deslypere JP
Am J Cardiol; 1994 May; 73(14):12D-17D. PubMed ID: 8198018
[TBL] [Abstract][Full Text] [Related]
5. Effects of alcohol consumption on pharmacokinetics, efficacy, and safety of fluvastatin.
Smit JW; Wijnne HJ; Schobben F; Sitsen A; de Bruin TW; Erkelens DW
Am J Cardiol; 1995 Jul; 76(2):89A-96A. PubMed ID: 7604808
[TBL] [Abstract][Full Text] [Related]
6. Development and pharmacology of fluvastatin.
Jokubaitis LA
Br J Clin Pract Suppl; 1996 Jan; 77A():11-5. PubMed ID: 8729584
[TBL] [Abstract][Full Text] [Related]
7. Development and pharmacology of fluvastatin.
Jokubaitis LA
Br J Clin Pract Suppl; 1994 Dec; (77):11-5. PubMed ID: 19489169
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of the combination of fluvastatin and gemfibrozil.
Spence JD; Munoz CE; Hendricks L; Latchinian L; Khouri HE
Am J Cardiol; 1995 Jul; 76(2):80A-83A. PubMed ID: 7604806
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia.
Sabia H; Prasad P; Smith HT; Stoltz RR; Rothenberg P
J Cardiovasc Pharmacol; 2001 May; 37(5):502-11. PubMed ID: 11336101
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of fluvastatin.
Scripture CD; Pieper JA
Clin Pharmacokinet; 2001; 40(4):263-81. PubMed ID: 11368292
[TBL] [Abstract][Full Text] [Related]
11. Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus.
Appel S; Rüfenacht T; Kalafsky G; Tetzloff W; Kallay Z; Hitzenberger G; Kutz K
Am J Cardiol; 1995 Jul; 76(2):29A-32A. PubMed ID: 7604792
[TBL] [Abstract][Full Text] [Related]
12. Absorption and disposition of fluvastatin, an inhibitor of HMG-CoA reductase, in the rabbit.
Tse FL; Labbadia D
Biopharm Drug Dispos; 1992 May; 13(4):285-94. PubMed ID: 1600114
[TBL] [Abstract][Full Text] [Related]
13. Fluvastatin administration at bedtime versus with the evening meal: a multicenter comparison of bioavailability, safety, and efficacy.
Dujovne CA; Davidson MH
Am J Med; 1994 Jun; 96(6A):37S-40S. PubMed ID: 8017465
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of fluvastatin and specific drug interactions.
Smith HT; Jokubaitis LA; Troendle AJ; Hwang DS; Robinson WT
Am J Hypertens; 1993 Nov; 6(11 Pt 2):375S-382S. PubMed ID: 8297546
[TBL] [Abstract][Full Text] [Related]
15. Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2.
Lindahl A; Sjöberg A; Bredberg U; Toreson H; Ungell AL; Lennernäs H
Mol Pharm; 2004; 1(5):347-56. PubMed ID: 16026004
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A.
Park JW; Siekmeier R; Lattke P; Merz M; Mix C; Schüler S; Jaross W
J Cardiovasc Pharmacol Ther; 2001 Oct; 6(4):351-61. PubMed ID: 11907637
[TBL] [Abstract][Full Text] [Related]
17. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine.
Holdaas H; Hartmann A; Stenstrøm J; Dahl KJ; Borge M; Pfister P
Am J Cardiol; 1995 Jul; 76(2):102A-106A. PubMed ID: 7604781
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
19. Outcome monitoring of fluvastatin in a Department of Veterans Affairs lipid clinic.
Kellick KA; Burns K; McAndrew E; Haberl E; Hook N; Ellis A
Am J Cardiol; 1995 Jul; 76(2):62A-64A. PubMed ID: 7604801
[TBL] [Abstract][Full Text] [Related]
20. The safety evaluation of fluvastatin, an HMG-CoA reductase inhibitor, in beagle dogs and rhesus monkeys.
Hartman HA; Myers LA; Evans M; Robison RL; Engstrom RG; Tse FL
Fundam Appl Toxicol; 1996 Jan; 29(1):48-62. PubMed ID: 8838639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
